apalutamide + androgen deprivation therapy + docetaxel

The STARTAR regimen is an intensified multi-modal salvage therapy combination being evaluated in a Phase 2 clinical trial (NCT03311503) led by **Andrew J. Armstrong, MD**, at Duke University. This regimen is specifically designed for men with PSA-recurrent, non-metastatic prostate cancer following a radical prostatectomy. It consists of a combination of **apalutamide** (a second-generation androgen receptor inhibitor), standard **androgen deprivation therapy (ADT)** (typically a GnRH agonist or antagonist), and **docetaxel** (a taxane chemotherapy), administered alongside salvage **radiation therapy**. The therapeutic rationale is to combine potent hormonal suppression with cytotoxic chemotherapy and local radiation to eradicate micrometastatic disease and improve long-term outcomes in high-risk patients who have failed primary surgical treatment.

Other names

STARTAR regimenApalutamide + ADT + DocetaxelIntensified Salvage Therapy